14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TAK vs TEVA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
TEVA Captures Overall Composite Edge (29.8 SELL vs 47.7 HOLD), While TAK Leads 4–1 on Growth & Valuation Pillars
TEVA Overall Winner
6-Pillar Tally: TAK 4 – 1 TEVA (1 Tie)
Matrix Metrics: TAK 6 – 4 TEVA
As of Nov 16, 2026, Teva Pharmaceutical Industries Limited (TEVA) captures the overall head-to-head institutional edge over Takeda Pharmaceutical Company Limited (TAK) on higher Unified Composite conviction (29.8/100 SELL vs. 47.7/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality), while TAK wins 4–1 across the 6-pillar growth and valuation breakdown. TAK trades at $21.61 (12.7x Forward P/E, 16.6% operating margin) versus TEVA at $43.01 (14.2x Forward P/E, 19.9% operating margin).
Composite vs. Pillar Nuance: While TAK currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. TEVA 29.8/100 SELL), TEVA captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (19.9% vs. 16.6% operating margin) and revenue trajectory (-1.9% vs. +6.7% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs TEVA. Trailing 12-month operating profitability (TAK 16.6% vs TEVA 19.9%) and valuation multiples (TAK 12.7x vs TEVA 14.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $51.1B market capitalization and 19.9% operating margin.
OpEx & R&D Reinvestment33.6% of Rev ($1.18B)
90D Engineering Disclosures0 Published
Investor FAQ TAK vs TEVA Key Questions & Quantitative Answers
As of Nov 16, 2026, Teva Pharmaceutical Industries Limited (TEVA) captures the overall head-to-head institutional edge over Takeda Pharmaceutical Company Limited (TAK) on higher Unified Composite conviction (29.8/100 SELL vs. 47.7/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality), while TAK wins 4–1 across the 6-pillar growth and valuation breakdown. TAK trades at $21.61 (12.7x Forward P/E, 16.6% operating margin) versus TEVA at $43.01 (14.2x Forward P/E, 19.9% operating margin). Composite vs. Pillar Nuance: While TAK currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. TEVA 29.8/100 SELL), TEVA captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (19.9% vs. 16.6% operating margin) and revenue trajectory (-1.9% vs. +6.7% YoY).
TAK leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with TEVA at -1.9% YoY revenue growth and -46.0% YoY earnings growth on $3.51B TTM revenue (53.5% gross margin, 19.9% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $3.51B for TEVA. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 33.6% of Rev ($1.18B) (0 disclosures) for TEVA.
TAK screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas TEVA trades at 14.2x Forward P/E, 101.8x Trailing P/E, 0.71x PEG, and 14.5x EV/Revenue (25.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus TEVA (6.7% ROE) capital efficiency.
In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, TEVA carries 25.5% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.51β · 29% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.